JP2022501351A - ６−（１−アクリロイルピペリジン−４−イル）−２−（４−フェノキシフェニル）ニコチンアミドの結晶形 - Google Patents

６−（１−アクリロイルピペリジン−４−イル）−２−（４−フェノキシフェニル）ニコチンアミドの結晶形 Download PDF

Info

Publication number
JP2022501351A
JP2022501351A JP2021515106A JP2021515106A JP2022501351A JP 2022501351 A JP2022501351 A JP 2022501351A JP 2021515106 A JP2021515106 A JP 2021515106A JP 2021515106 A JP2021515106 A JP 2021515106A JP 2022501351 A JP2022501351 A JP 2022501351A
Authority
JP
Japan
Prior art keywords
type
xrpd
shaped
phenoxyphenyl
acryloylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021515106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501351A5 (https=
Inventor
チェン、シャンヤン
ワン、ズオペン
イー、リーチン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of JP2022501351A publication Critical patent/JP2022501351A/ja
Publication of JP2022501351A5 publication Critical patent/JP2022501351A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021515106A 2018-09-18 2019-09-18 ６−（１−アクリロイルピペリジン−４−イル）−２−（４−フェノキシフェニル）ニコチンアミドの結晶形 Pending JP2022501351A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732994P 2018-09-18 2018-09-18
US62/732,994 2018-09-18
PCT/CN2019/106433 WO2020057549A1 (en) 2018-09-18 2019-09-18 Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Publications (2)

Publication Number Publication Date
JP2022501351A true JP2022501351A (ja) 2022-01-06
JP2022501351A5 JP2022501351A5 (https=) 2022-09-12

Family

ID=69888278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515106A Pending JP2022501351A (ja) 2018-09-18 2019-09-18 ６−（１−アクリロイルピペリジン−４−イル）−２−（４−フェノキシフェニル）ニコチンアミドの結晶形

Country Status (11)

Country Link
US (1) US11945792B2 (https=)
EP (1) EP3853217B1 (https=)
JP (1) JP2022501351A (https=)
KR (1) KR20210060501A (https=)
CN (2) CN112654607B (https=)
AU (1) AU2019341284B2 (https=)
CA (1) CA3111114A1 (https=)
ES (1) ES2951420T3 (https=)
MX (1) MX2021003064A (https=)
SG (1) SG11202102116XA (https=)
WO (1) WO2020057549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531893A (ja) * 2013-09-30 2016-10-13 ベイジン・シナーケアー・ファーマ・テク・カンパニー、リミテッドＢｅｉｊｉｎｇ Ｓｙｎｅｒｃａｒｅ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ｂｔｋの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用
CN107257686A (zh) * 2014-12-18 2017-10-17 普林斯匹亚生物制药公司 天疱疮的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531893A (ja) * 2013-09-30 2016-10-13 ベイジン・シナーケアー・ファーマ・テク・カンパニー、リミテッドＢｅｉｊｉｎｇ Ｓｙｎｅｒｃａｒｅ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ｂｔｋの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用
CN107257686A (zh) * 2014-12-18 2017-10-17 普林斯匹亚生物制药公司 天疱疮的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
塩路雄作, 固形製剤の製造技術, vol. 普及版, JPN6011023134, 27 January 2003 (2003-01-27), pages 9 - 12, ISSN: 0005423772 *
社団法人日本化学会編, 第４版実験化学講座１基本操作Ｉ, vol. 第１８４−１８９頁, JPN7008003682, 5 April 1996 (1996-04-05), ISSN: 0005423773 *

Also Published As

Publication number Publication date
CN116496247A (zh) 2023-07-28
AU2019341284A1 (en) 2021-04-15
CN112654607B (zh) 2023-01-13
CA3111114A1 (en) 2020-03-26
EP3853217A1 (en) 2021-07-28
WO2020057549A1 (en) 2020-03-26
EP3853217B1 (en) 2023-06-07
US11945792B2 (en) 2024-04-02
CN112654607A (zh) 2021-04-13
AU2019341284B2 (en) 2024-09-05
KR20210060501A (ko) 2021-05-26
SG11202102116XA (en) 2021-04-29
ES2951420T3 (es) 2023-10-20
US20210188801A1 (en) 2021-06-24
MX2021003064A (es) 2021-05-27
EP3853217A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
US12419877B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105848718B (zh) Aramchol盐
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
KR20170078710A (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
JP2022545195A (ja) 塩
EP2817300B1 (en) Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
JP2022501351A (ja) ６−（１−アクリロイルピペリジン−４−イル）−２−（４−フェノキシフェニル）ニコチンアミドの結晶形
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
HK40096475A (zh) 6-(1-丙烯醯基哌啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的晶型
KR20260046314A (ko) (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
KR20240146734A (ko) 피마살탄의 신규 염 및 이의 제조방법
HK40048993A (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
KR20260056135A (ko) 갑상선 안질환 치료를 위한 린시티닙의 결정질염
HK40048993B (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
HK40015773A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1226347B (zh) Aramchol盐
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220902

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240703

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241004